Verastem (VSTM) Free Cash Flow (2011 - 2026)
Verastem (VSTM) posted quarterly Free Cash Flow of -$52.1 million for Q1 2026, down 34.75% year-over-year from -$79.9 million in Q1 2025, and down 73.99% quarter-over-quarter from -$30.0 million in Q4 2025.
Powered by 
Analysis
Verastem (VSTM) Free Cash Flow (2011 - 2026) Analysis & Trends
Verastem's Free Cash Flow history runs 16 years deep, the most recent figure standing at -$52.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 34.75% year-over-year to -$52.1 million; the TTM figure through Mar 2026 stood at -$150.9 million (down 31.08% YoY), while the FY2025 annual figure was -$137.5 million, down 31.21% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$52.1 million, down from -$30.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$12.7 million in Q2 2022, with the low at -$52.1 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$25.1 million (2024), against an average of -$26.2 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow plunged 78.63% in 2023, then gained 15.44% in 2024.
- Verastem's Free Cash Flow stood at -$16.6 million in 2022, then slumped by 78.63% to -$29.7 million in 2023, then increased by 15.44% to -$25.1 million in 2024, then dropped by 19.34% to -$30.0 million in 2025, then plunged by 73.99% to -$52.1 million in 2026.
- Business Quant data shows VSTM's Free Cash Flow at -$52.1 million in Q1 2026, -$30.0 million in Q4 2025, and -$36.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | -43.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.91 Mn |
| Mar 31, 2026 | -52.12 Mn |
| Dec 31, 2025 | -29.95 Mn |
| Sep 30, 2025 | -36.22 Mn |
| Jun 30, 2025 | -32.66 Mn |
| Mar 31, 2025 | -38.68 Mn |
| Dec 31, 2024 | -25.10 Mn |
| Sep 30, 2024 | -23.80 Mn |
| Jun 30, 2024 | -27.58 Mn |
| Mar 31, 2024 | -28.33 Mn |
| Dec 31, 2023 | -29.68 Mn |
| Sep 30, 2023 | -16.59 Mn |
| Jun 30, 2023 | -19.90 Mn |
| Mar 31, 2023 | -20.29 Mn |
| Dec 31, 2022 | -16.62 Mn |
| Sep 30, 2022 | -15.08 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -19.28 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -10.83 Mn |